TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04251533
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg orally, once per day (QD), tablets
Study: NCT03913442
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0.8 mg or 0.6 mg orally once daily for 3 months
Study: NCT00784212
Drug: BGG492
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00784212
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02224521
Drug: GSK2190915 Granule Capsule (A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915A granule filled in to Gelatin capsules
Study: NCT02224521
Drug: GSK2190915 Semi-solid Lipid Capsule (B)
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915A dispersed in a lipid vehicle and filled in to HPMC capsules
Study: NCT02224521
Drug: GSK2190915 Liquid Lipid Capsule (C)
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915A dissolved in lipid vehicle milled and filled in to Gelatin capsules
Study: NCT02224521
Drug: GSK2190915 Milled Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915A granule is blended, compressed into tablets and aqueous film coated
Study: NCT02224521
Drug: GSK2190915 Micronised Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2190915A granule is blended, compressed into tablets and aqueous film coated
Study: NCT01299038
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taken orally once a day for 4 weeks
Study: NCT00312000
Drug: capecitabine-irinotecan
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1. st line capecitabine 1250 mg/m2 orally b.i.d. on day 1-14~2. nd line q 3 w irinotecan 350 mg/m2 IV infusion on day 1
Study: NCT00312000
Drug: capecitabine+irinotecan (1st line)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: q 3 w irinotecan 250 mg/m2 IV infusion in 30 minutes on day 1 2 hours after discontinuation of the infusion followed by capecitabine 1000 mg/m2 orally b.i.d. on day 1-14
Study: NCT03629340
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) BID (two times each day) for 12 weeks
Study: NCT04495621
Drug: MEN1611
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEN1611 oral dose administered twice daily for a continuous 28-day cycle.
Study: NCT02160782
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally once daily during randomized withdrawal period
Study: NCT00195572
Drug: Isovorin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01638767
Drug: Contraceptives, Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.150 mg desogestrel and 0.030 mg ethinyl estradiol tablets, USP. One tablet per day at the same time each day, from the beginning of the menstrual cycle.
Study: NCT01638767
Drug: Contraceptive, Vaginal ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: etogestrel/ ethinyl estradiol slow release vaginal ring (11.4 mg/2.6 mg) to deliver 120 mcg etonogestrel/15 mcg ethinyl estradiol per day
Study: NCT03309800
Drug: HL301
Normalized name: Hydrocodone and Levorphanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
Study: NCT03576885
Drug: inhaled nitric oxide
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled nitric oxide will be administered starting at 20 ppm. Treatment will continue for 14 days or until resolution of pulmonary hypertension
Study: NCT03576885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo will be administered starting at 20 ppm. Treatment will continue for 14 days or until resolution of pulmonary hypertension
Study: NCT00555009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection, with dummy dose titration for a total duration of 36 weeks.
Study: NCT03581773
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg pr day for 12 weeks
Study: NCT03581773
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo pill pr day for 12 weeks
Study: NCT03337607
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 200 mg per day for moderate pain (Numerical Rating Scale score 4-6 on an 11-point scale where 0 indicates no pain and 10 indicates worst imaginable pain), or 2 x 200 mg per day (Numerical Rating Scale 7-10), respectively, for four weeks
Study: NCT03339882
Drug: Remifemin
Normalized name: Remifemin Menopause Relief Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifemin 0.2g po bid\*12 weeks at the beginning of the LHRH-a treatment
Study: NCT02449291
Drug: APD421
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02449291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01452529
Drug: Hydrocodone bitartrate q24h film-coated tablets
Normalized name: hydrocodone
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
Study: NCT01452529
Drug: Placebo to match hydrocodone bitartrate q24h tablets
Normalized name: Hydrocodone Bitartrate
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo to match hydrocodone bitartrate q24h film coated tablets 20 - 120 mg once daily
Study: NCT00403286
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation Solution for nebulization 2 mL bid for 2 weeks
Study: NCT02884206
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 50, 100, and 200 mg tablets taken orally twice daily with matching placebo for valsartan
Study: NCT02884206
Drug: Placebo of LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match LCZ696 50 mg, 100 mg, and 200 mg tablets
Study: NCT00398411
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet per day p.o.
Study: NCT00950742
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose cohorts from low dose to MTD
Study: NCT00608205
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02668783
Drug: Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring
Normalized name: estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Up to 4 cycles (or 6 cycles if also participating in the extension) of ENG-E2 125 μg/300 μg administered intravaginally. Each cycle will consist of 21 days of vaginal ring use followed by 7 ring-free days.
Study: NCT02668783
Drug: Placebo vaginal ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 4 cycles (or 6 cycles if also participating in the extension) of placebo administered intravaginally. Each cycle will consist of 21 days of placebo vaginal ring use followed by 7 ring-free days.
Study: NCT02668783
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen tablets, to be taken orally, will be provided for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may take 400 mg every 4 hours as needed for pelvic pain/cramping, or as instructed by their physician according to local labeling for relief of menstrual pain.
Study: NCT01417897
Drug: Regular human insulin
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
Study: NCT01630200
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning
Study: NCT00585390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil capsule
Study: NCT00356720
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03141060
Drug: Optimized multidrug background regimen (OBR) for children with MDR-TB
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-study prescribed OBR will vary according to local, national, and/or international guidelines for treatment of children with MDR-TB. Administered in addition to DLM for 24 weeks.
Study: NCT00149292
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01797120
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Everolimus (2 tablets) daily x 12 cycles. Placebo manufactured to mimic everolimus tablet.
Study: NCT00679523
Drug: AN2690 Solution, 5.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application for 180 days
Study: NCT00679523
Drug: AN2690 Solution, 7.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application for 180 days
Study: NCT03811535
Drug: Norditropin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norditropin® will be administered s.c. once daily by FlexPro® pen-injector. Norditropin® should be injected daily in the evening. The dose will be calculated based on the subject's current body weight.
Study: NCT02858310
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part of the non-myeloablative lymphocyte-depleting preparative regimen.
Study: NCT01436916
Drug: placebo + life style counselling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will provide placebo 10 sachets loading and then single sachet fortnightly for 6 months
Study: NCT01795638
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile water, 0.4 ml/kg every 6 hours on days of life 7-35.
Study: NCT01613365
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oropharyngeal and nasopharyngeal decontamination with placebo
Study: NCT03192059
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Efficacy of the combined treatment
Study: NCT00265551
Drug: SCA-136 (200 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00265551
Drug: SCA-136 (400 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00265551
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00063128
Drug: human insulin inhalation powder (HIIP)
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Administer HIIP within 15 minutes before meals.~* Administer doses in one-capsule increments equivalent to approximately 2 IU or 6 IU of subcutaneous insulin.~* Target treatment goals during the treatment sequence are the same as for patients using preprandial injectable insulin
Study: NCT02691897
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin 3mg once daily at bedtime
Study: NCT02691897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 tablet once daily at bedtime
Study: NCT04467697
Drug: SOV2012-F1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral preparation of testosterone undecanoate (TU). Strengths of 100 mg TU, 150 mg TU and 200 mg TU
Study: NCT00886665
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, 4 g, powder, oral, 3 times a day
Study: NCT01927757
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Background methotrexate at least 15 mg weekly
Study: NCT04480463
Drug: SCD411
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVT (intravitreal) injection
Study: NCT03540810
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive placebo with their usual treatment
Study: NCT01973569
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo administered subcutaneously to match denosumab
Study: NCT03820180
Drug: Test Product
Normalized name: Patch test product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT03820180
Drug: Reference Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT00794781
Drug: E6201
Normalized name: TRACH STOMA PROTECTOR,CLOTH WHITE BE6201
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6201 Part A (Dose Escalation): Intravenous (IV) infusion administered over 30 minutes once weekly for 3 weeks (Days 1, 8, and 15). The first 3 to 6 subjects of the first cohort will receive 20 mg/m\^2/week for a cycle of 3 weeks followed by a 1-week rest period. Subsequent dose escalations may increase at increments of 100% until two Grade 2 toxicities or 1 dose-limiting toxicity (DLT) are observed in a dose group. Thereafter, doses will be increased in increments of 50% or less until the maximum tolerated dose (MTD) is determined. Part B (MTD Expansion): After the MTD is determined in Part A, 15 additional subjects will continue to receive cycles at the MTD.
Study: NCT03257462
Drug: SPR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPR001 Capsules
Study: NCT03350165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 matching placebo tablet
Study: NCT04028063
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin is the standard of care first-line therapy for most subtypes of metastatic soft tissue sarcomas. Doxorubicin monotherapy administered at 75 mg/m2 has resulted in objective response rate of 14%, and median progression-free survival of 4.6 months, and another study reported progression-free survival at 6 months of 46.3%, with a median PFS of 5.8 months, and best objective response rate of 19%.
Study: NCT02601313
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT00419926
Drug: Enteric-coated mycophenolate sodium (Myfortic)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1440 mg/day for the standard dose. 2880 mg/day for the initial intensified dosage, reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
Study: NCT03745625
Drug: HSK3486
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-stage:after an initial dose of 1mg/kg/h, If the BIS is in the range of 80 to 60 and the continuous RASS score = 3 or one time RASS score ≤ -4, the 0.4 mg/kg/h maintenance dose is administered. The total infusion time was 4h.~Second-stage: a single loading dose of 0.2 mg/kg given over 1 minute, then a continuous infusion of maintenance dose 0.35 mg/kg/h for a total infusion time of 12h.
Study: NCT01460251
Drug: DiaPep277
DrugBank: DiaPep 277 (DB06651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg DiaPep277® administered every 3 months.For patients who just completed the 2-year 901 study, a 3-year extended treatment will be offered with 13 administrations; patients who completed the 2-year 910 extension study will be offered a 3rd year of treatment with 5 additional administrations.
Study: NCT02556203
Drug: Acetylsalicylic Acid (ASA)
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75-100mg OD
Study: NCT02556203
Drug: Vitamin K antagonist (VKA)
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: In case of NOAF, Open-label VKA therapy to target international normalized ratio (INR) 2-3, according to guidelines
Study: NCT03980379
Drug: 304 injection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monoclonal antibodies, 100mg/10ml per injection
Study: NCT00528827
Drug: Cardene® I.V.
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 5 mcg/kg/min Cardene I.V.~* 2.5 mcg/kg/min Cardene I.V.~* 0.5 mcg/kg/min Cardene I.V.
Study: NCT00176787
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01818570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 100 ml placebo solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
Study: NCT03967795
Drug: N2-L-Alanyl-L-Glutamine (Substance)
Normalized name: L-Alanyl-L-glutamine
DrugBank: Alanyl glutamine (DB11876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 gr of 10% N2-L-Alanyl-L-Glutamine, dilution in 200 ml of water for injection, intravenous perfusion over 30 minutes
Study: NCT02350530
Drug: FOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
Study: NCT02600169
Drug: Pemprolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma.
Study: NCT00092859
Drug: MK0557
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03892785
Drug: Methotrexate treatment
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate subcutaneous from W0 to W51 (52 administrations).~* W0: 7.5 mg/week~* W1: 0.2 mg/Kg/week~* W2 to W51: 0.3 mg/Kg/week (without exceeding 20 mg/week) Folic acid 10 mg/week, 48h after taking Methotrexate, from W0 to W51
Study: NCT01937364
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical appearing placebo every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
Study: NCT06224582
Drug: Yinxingmihuan oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yinxingmihuan oral solution is made of Ginkgo leaf extract and armillariella mellea powders.
Study: NCT04131413
Drug: pNGVL4aCRTE6E7L2
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose escalation will start from the lowest dose level of 0.3 mg. This dose cohort will consist of 3 participants and a monitoring period of one week after the final dose mandated. If there are 0 participants in the 0.3 dose level cohort that experience dose limiting toxicities (DLT), a new cohort of 3 participants will be vaccinated at the 1.0 mg dose level. If there are 0 participants in the 1.0 mg dose level that experience DLT, then a new cohort of 3 participants will be vaccinated at the 3.0 mg dose level. If there is 1 participant experiencing DLTs, an additional cohort of 3 subjects will be enrolled and treated at the current dose level. If there are 2 or more participants experiencing DLTs in the 3 or additional cohort of 3 vaccinated at the current dose level, then the next lower dose level will be determined as the Maximum Tolerated Dose (MTD).
Study: NCT04159415
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) infusion loading dose or subcutaneous (SC) injection weekly (QW).
Study: NCT04159415
Drug: High-dose REGN4461
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion loading dose or SC injection QW.
Study: NCT06224582
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo oral solution is in the same appearance, color, smell and taste as the experimental Yinxingmihuan oral solution.
Study: NCT04171765
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive subcutaneous (SC) placebo matched to BFKB8488A.
Study: NCT04171765
Drug: BFKB8488A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive subcutaneous (SC) BFKB8488A.
Study: NCT02503423
Drug: ASTX660
Approvals — FDA: no, EMA: no, PMDA: no
Description: described above
Study: NCT01439100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy tablet
Study: NCT03198078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily, tablets
Study: NCT00691067
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03161093
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: Capsule
Study: NCT03161093
Drug: Naproxen-matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT01415895
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects will receive 1 placebo capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
Study: NCT02966873
Drug: Inactive Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will receive 12 weeks of inactive placebo. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.
Study: NCT04196413
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 500 mg/m2 per day IV for days -4, -3, -2
Study: NCT03666000
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT03866408
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upper body obese subjects will be block randomized to pioglitazone or placebo at enrollment.
Study: NCT03401593
Drug: midazolam with fentanyl
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Radio-frequency catheter ablation is performed in the post-absorptive state after sedation with midazolam and fentanyl. Multipolar catheters were positioned in the coronary sinus, His, and the right atrium. The three-dimensional LA geometry was reconstructed using a CARTO or NavX electroanatomical mapping system. Circumferential pulmonary vein isolation was performed in all patients using a irrigated-tip catheter. A circular mapping catheter was used to confirm the isolation of the pulmonary veins. Successful ablation was defined by the elimination of all the pulmonary vein potentials along the antrum or inside the veins. If the AF was not terminated after elimination of all the pulmonary vein potentials, linear ablation and complex fragmented atrial electrogram ablation were performed.
Study: NCT00744276
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo topically applied once daily for 4 treatment cycles